A positive outcome from a meeting of the US regulator’s scientific panel lifted shares in Australian biotech Mesoblast (ASX: MSB) by more than half on Friday.
The stem cell specialist received a nine-to-one vote in favor of approving Ryoncil (remestemcel-L) in acute pediatric graft versus host disease (GVHD).
While the US Food and Drug Administration is not bound to follow the advice, it normally does. A full review will lead to a decision by the end of September.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze